Multi-targeted antifolate therapy for non-small cell lung cancer and mesothelioma;Multi-targeted antifolate dans le traitement du cancer bronchique non à petites cellules et du mésothéliome

Anti-Cancer Drugs

Volumn 12, Issue SUPPL. 3, 2001, Pages

  Le Chevalier, T ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Antimetabolite; Mesothelioma; Multi targeted antifolate; Non small cell lung cancer

Indexed keywords

ANTIMETABOLITE; CISPLATIN; DOCETAXEL; FOLIC ACID ANTAGONIST; GEMCITABINE; LOMETREXOL; METHOTREXATE; PLATINUM DERIVATIVE; RALTITREXED;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG STRUCTURE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; MONOTHERAPY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RASH; VOMITING;

EID: 0034892254     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200107003-00005     Document Type: Conference Paper

References (13)

1. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl] benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase
2. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation
3. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
4. Phase I and pharmacokinetic study of LY231514, the multi-targeted antifolate, administered by daily × 5, q21 schedule
5. Activity of the multi-targeted antifolate MTA (LY231514) in advanced non-small cell lung cancer
6. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study
7. Phase II trial of MTA (LY231514) in patients with non-small cell lung cancer who relapsed after previous platinum or non-platinum chemotherapy
8. Treatment regimens including the multitargeted antifolate LY231514 (MTA) in tumor xenografts
9. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin
10. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA TM) and cisplatin: A multicenter phase II trial
11. Phase II study of MTA (Alimta) and cisplatin in patients with advanced non-small cell cell lung cancer (NSCLC)
12. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
13. ALIMTA in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial